This database contains 33 studies, archived under the term: "galantamine"
Click here to filter this large number of results.
Galantamine (reminyl) in the treatment of severe Alzheimer’s disease
Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the […]
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Nordberg, Agneta,
Darreh-Shori, Taher,
Peskind, Elaine,
Soininen, Hilkka,
Mousavi, Malahat,
Eagle, Gina,
Lane, Roger
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]
Trospium and cognition in patients with late onset Alzheimer disease
Objectives: Cholinesterase inhibitors for the treatment of Alzheimer’s Disease (AD) and antimuscarinic agents for the treatment of urge urinary incontinence (UUI) may reduce the potential effect of each other in the patients with both diseases. Trospium has a relatively low lipophilicity and low CNS penetration, and galantamine, a cholinesterase inhibitors, has also allosterically modulates nicotinic […]
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study
Bokde, Arun L. W.,
Karmann, Michaela,
Teipel, Stefan J.,
Born, Christine,
Lieb, Martin,
Reiser, Maximilian F.,
Möller, Hans-Jürgen,
Hampel, Harald
Visual perception has been shown to be altered in Alzheimer disease (AD) patients, and it is associated with decreased cognitive function. Galantamine is an active cholinergic agent, which has been shown to lead to improved cognition in mild to moderate AD patients. This study examined brain activation in a group of mild AD patients after […]
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Burns, Alistair,
Bernabei, Roberto,
Bullock, Roger,
Cruz Jentoft, Alfonso J.,
Frölich, Lutz,
Hock, Christoph,
Raivio, Minna,
Triau, Eric,
Vandewoude, Maurits,
Wimo, Anders,
Came, Elizabeth,
Van Baelen, Bart,
Hammond, Gerry L.,
van Oene, Joop C.,
Schwalen, Susanne
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease
Feldman, Howard H.,
Pirttila, Tuula,
Dartigues, Jean-François,
Everitt, Brian,
Van Baelen, Bart,
Schwalen, Susanne,
Kavanagh, Shane
Objective: This study evaluated patient and treatment (galantamine and other acetylcholinesterase inhibitors (AChEIs)) factors associated with the time until nursing home placement (NHP) in patients with Alzheimer’s disease (AD) with and without cerebrovascular disease (CVD).; Methods: Re-contact follow-up study conducted in 2004 of 548 patients who had previously participated in RCTs with galantamine. Time to […]
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
Taipale, Heidi,
Tanskanen, Antti,
Koponen, Marjaana,
Tolppanen, Anna-Maija,
Tiihonen, Jari,
Hartikainen, Sirpa
The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer’s disease diagnosed during the […]